Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Citizens Jmp

Citizens Jmp started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research report sent to investors on Monday, MarketBeat Ratings reports. The firm issued an outperform rating and a $52.00 price objective on the stock.

Several other brokerages also recently issued reports on AVTX. Wall Street Zen upgraded shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Guggenheim assumed coverage on shares of Avalo Therapeutics in a research report on Monday, February 2nd. They set a “buy” rating and a $50.00 price objective for the company. Mizuho upgraded shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. HC Wainwright raised their price objective on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Finally, BTIG Research restated a “buy” rating and set a $40.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.20.

Avalo Therapeutics Stock Performance

Shares of NASDAQ:AVTX opened at $16.27 on Monday. Avalo Therapeutics has a 52-week low of $3.39 and a 52-week high of $20.72. The company has a market capitalization of $370.79 million, a P/E ratio of -2.84 and a beta of 0.93. The company has a 50-day simple moving average of $15.55 and a 200 day simple moving average of $16.07.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to analyst estimates of ($0.21) million. As a group, equities analysts forecast that Avalo Therapeutics will post -19.07 earnings per share for the current year.

Insider Activity at Avalo Therapeutics

In other news, CFO Christopher Ryan Sullivan sold 7,980 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $17.15, for a total transaction of $136,857.00. Following the transaction, the chief financial officer directly owned 17,338 shares of the company’s stock, valued at approximately $297,346.70. This trade represents a 31.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 25,492 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the transaction, the insider directly owned 3,622 shares in the company, valued at $58,495.30. This represents a 87.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 42,130 shares of company stock valued at $693,225 over the last 90 days. Company insiders own 3.03% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. BIT Capital GmbH bought a new position in shares of Avalo Therapeutics during the third quarter worth approximately $25,000. PFS Partners LLC increased its holdings in shares of Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after purchasing an additional 1,000 shares during the period. Boothbay Fund Management LLC bought a new position in shares of Avalo Therapeutics during the second quarter worth approximately $56,000. Dimensional Fund Advisors LP bought a new position in shares of Avalo Therapeutics during the third quarter worth approximately $143,000. Finally, Jump Financial LLC bought a new position in shares of Avalo Therapeutics during the fourth quarter worth approximately $238,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.